BPC-157 and Prednisone Interaction: What Patients and Clinicians Need to Know

Is there a known interaction between BPC-157 and prednisone?

No interaction is documented. A 2026 systematic review searched Embase, PubMed, the Cochrane Library and ClinicalTrials.gov through June 1, 2026 and found three human studies of BPC-157, 30 patients in total: a retrospective review of knee injections, a single-arm pilot of bladder-wall injections for interstitial cystitis, and a two-person intravenous safety pilot [1]. None was a drug-interaction study. The reviewers rated all three poor in methodological quality and the overall certainty of evidence very low [1].

FDA's own 2026 review of BPC-157 identified five small human reports (conference abstracts, a retrospective chart review, a single-arm pilot and a two-person pilot) and found no human pharmacokinetic data for BPC-157 taken by mouth, injected under the skin, given as a nasal spray, or applied to the skin [2].

Why BPC-157's pharmacology cannot answer the question

FDA's reviewers wrote in July 2026 that BPC-157's molecular targets have not been identified, that its mechanisms remain poorly understood, and that dose-response relationships for its reported protective effects were never established; those reported effects, such as preventing colonic fistulas and gut or liver lesions, come from rat studies [2].

Absorption is also unmapped. After rectal enemas in two early studies, BPC-157 was mostly undetectable in blood, and FDA judged that it appears not to be absorbed systemically by that route [2]. For oral, subcutaneous, nasal and skin use there is no human pharmacokinetic measurement of any kind [2]. That cuts both ways: no measurement shows BPC-157 changing how prednisone is broken down, and no measurement shows it does not.

What prednisone does that a second substance could add to

Blood glucose. In a one-month hospital review, 50 patients received at least 40 mg/day of prednisone equivalent for two or more days and had glucose measured; 32 of them (64%) had at least one reading of 200 mg/dL or higher, and among the 34 with no history of diabetes, 19 (56%) had at least one such reading [3]. This was a small single-center study.

Infection. Pooling 71 controlled trials, infectious complications occurred in 12.7% of 2,111 patients given systemic corticosteroids versus 8.0% of 2,087 controls (relative risk 1.6, 1.3 to 1.9), with no increase at daily doses below 10 mg or cumulative doses below 700 mg of prednisone [4].

Bone. In a UK general-practice cohort of 244,235 oral corticosteroid users and matched controls, the relative rate was 2.60 for vertebral fracture and 1.61 for hip fracture, rising with dose: the vertebral fracture rate ratio was 1.55 below 2.5 mg/day of prednisolone and 5.18 at 7.5 mg or more [5]. The American College of Rheumatology strongly recommends fracture-risk assessment for adults taking at least 2.5 mg/day for more than three months, and drug treatment for those at medium, high or very high fracture risk [6].

Short courses. In US claims covering 1,548,945 adults, 21.1% received at least one short course of oral corticosteroids over three years; within 30 days of starting, rates were higher for sepsis (incidence rate ratio 5.30), venous thromboembolism (3.33) and fracture (1.87), and the increase persisted below 20 mg/day of prednisone equivalent [7]. These are observational data.

Stomach and gut bleeding. Here another drug class is known to change prednisone's risk. In a Tennessee Medicaid case-control study of 1,415 ulcer cases and 7,063 controls, the relative risk for current corticosteroid users was 1.1 (0.5 to 2.1) without an NSAID and 4.4 (2.0 to 9.7) with one [8]. A meta-analysis of 159 randomized trials (33,253 patients) put the overall odds ratio for gastrointestinal bleeding or perforation with corticosteroids at 1.43 (1.22 to 1.66) [9].

Can BPC-157 offset prednisone side effects?

No human study has tested that. What exists is small. A retrospective review followed 17 patients who had BPC-157 injected into the knee, 16 of whom were reached by phone; 11 of the 12 who received BPC-157 alone reported significant improvement, with no control group, no validated outcome tools and recalled results [10]. A single-arm pilot injected a total of 10 mg around the bladder wall in 12 women who had not responded to pentosan polysulfate; 10 reported complete symptom resolution and 2 about 80%, all patient-rated and without a placebo arm [11]. A two-person pilot gave 10 mg then 20 mg intravenously and reported no measurable change in tested heart, liver, kidney, thyroid or glucose markers and no side effects [12].

None of these studies was designed to look at steroid side effects such as wound healing, muscle wasting or bone loss. The 2026 reviewers concluded that BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [1].

Blood glucose while both are in play

Prednisone's effect on glucose is well documented [3]. BPC-157's effect in people is not. The only human glucose measurement comes from the intravenous pilot, which found no measurable change at 10 mg and 20 mg in two adults, one dose each day [12]; that is too small and too short to describe an effect. In 28-day intramuscular animal toxicity studies, BPC-157 raised glucose, ALT and triglyceride levels and altered clotting time, shortening aPTT in rats and prolonging it in dogs [2]. FDA found no human studies of BPC-157 given by mouth, subcutaneous injection, nasal spray or skin [2].

What is documented about BPC-157's own safety

FDA searched its adverse-event database through December 4, 2025 and found three reports, all for injectable BPC-157: injection-site redness and swelling lasting nine days in a patient who also used compounded thymosin; shortness of breath leading to an emergency room visit; and widespread skin and gum darkening that recurred on re-exposure to a product containing BPC-157 plus TB-500. FDA said it could not tell whether BPC-157 caused any of them [2]. Its conclusion was that there is insufficient clinical safety information to characterize the peptide's safety profile [2].

The agency's stated compounding concerns are immunogenicity for certain routes, peptide-related impurities, and difficulty characterizing the active ingredient; it also said it lacked sufficient information to know whether the drug would cause harm in humans [13]. BPC-157 is not an FDA-approved drug, has no US Pharmacopeia or National Formulary monograph, and FDA's July 2026 review found no approved product containing it in any country it searched [2]. It sat in FDA's category 2 table of substances that may present significant safety risks from September 2023 until April 22, 2026, when it moved to a table of substances whose nominators had withdrawn their nominations, a change in listing status and not a finding of safety [13]. Neither the July 2026 advisory-committee vote nor the October 2026 draft HHS enforcement-discretion policy approves it or places it on FDA's list [14][15].

Bottom line

Prednisone's documented risks include high blood glucose, infection, fracture, and gastrointestinal bleeding when combined with an NSAID [3][4][5][8]. BPC-157 is an unapproved peptide with a human safety record FDA calls insufficient and no pharmacokinetic data for oral, subcutaneous, nasal or skin use [2][13]. No human study has measured whether adding BPC-157 changes any of prednisone's risks, so the evidence supports neither a claim that the two are dangerous together nor a claim that they are safe together.